Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well erlotinib hydrochloride and bevacizumab work in treating
patients with stage IV breast cancer. Erlotinib hydrochloride may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving
erlotinib hydrochloride and bevacizumab may be an effective treatment for breast cancer.